Our goal is to improve outcomes and standards of care in cancerous and non-cancerous treatments. Clinical studies have demonstrated that when used in conjunction with chemotherapy for breast cancer, Medifocus’ patented APA system can significantly increase tumor shrinkage by 50 percent. For BPH, the Prolieve system has shown it can significantly decrease the American Urological Association (AUA) symptom scores.